We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App





Treatment of Critically Ill COVID-19 Patients with Blood Purification Device Doubles Survival Rate

By HospiMedica International staff writers
Posted on 13 Jan 2022
Print article
Image: Seraph 100 Microbind Affinity Blood Filter (Photo courtesy of ExThera Medical Corporation)
Image: Seraph 100 Microbind Affinity Blood Filter (Photo courtesy of ExThera Medical Corporation)

Critically ill patients treated with a blood purification device within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released study.

The study found that survivability in ICU COVID patients that began treatment with ExThera Medical Corporation’s (Martinez, CA, USA) Seraph 100 Microbind Affinity Blood Filter within 60 hours of ICU admission was 65.5% while it was 37.5% in patients that started the treatment after more than 60 hours in the ICU. Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 800 US and EU patients with COVID-19 since April 2020. The Seraph 100 is CE marked and commercially available in the EU and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

As a patient's blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

“Few treatments are available for critically ill COVID patients in the ICU. We have already seen data that demonstrates survival improvement1 – and now additional peer-reviewed data was generated that demonstrates ‘earlier is better’ when it comes to Seraph 100 use in the ICU,” said Robert Ward, ExThera Medical Chairman. “In addition, patients treated earlier in their ICU with the Seraph 100 may avoid intubation and mechanical ventilation.”

Related Links:
ExThera Medical Corporation 


Print article

Channels

Critical Care

view channel
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign... Read more

Surgical Techniques

view channel
Image: Bio-glue enables near-instantaneous gelling, sealing and healing of injured tissue (Photo courtesy of Pexels)

Game-Changing ‘Bio-Glue’ Could End Use of Surgical Sutures and Staple

Tissue adhesive washout and detachment are major issues for medical practitioners and may prove fatal for patients, especially when the separation happens in vital organs like the lungs, liver and the heart.... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.